Book contents
- Cambridge Handbook of Pain Medicine
- Cambridge Handbook of Pain Medicine
- Copyright page
- Contents
- Contributors
- Pain Handbook Introduction
- Part I Introduction to Pain: Pain Signaling Pathways
- Part II Common Categories of Pharmacologic Medications to Treat Chronic Pain
- Chapter 4 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Chapter 5 Acetaminophen
- Chapter 6 Topicals
- Chapter 7 Muscle Relaxants
- Chapter 8 Opioids
- Chapter 9 Antineuropathic Medications
- Chapter 10 Cannabinoids
- Part III Chronic Pain Conditions Head and Neck
- Part IV Spine
- Part V Extremities
- Part VI Misc
- Part VII Adjunctive Therapy
- Index
- References
Chapter 10 - Cannabinoids
from Part II - Common Categories of Pharmacologic Medications to Treat Chronic Pain
Published online by Cambridge University Press: 01 December 2023
Book contents
- Cambridge Handbook of Pain Medicine
- Cambridge Handbook of Pain Medicine
- Copyright page
- Contents
- Contributors
- Pain Handbook Introduction
- Part I Introduction to Pain: Pain Signaling Pathways
- Part II Common Categories of Pharmacologic Medications to Treat Chronic Pain
- Chapter 4 Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- Chapter 5 Acetaminophen
- Chapter 6 Topicals
- Chapter 7 Muscle Relaxants
- Chapter 8 Opioids
- Chapter 9 Antineuropathic Medications
- Chapter 10 Cannabinoids
- Part III Chronic Pain Conditions Head and Neck
- Part IV Spine
- Part V Extremities
- Part VI Misc
- Part VII Adjunctive Therapy
- Index
- References
Summary
The use of cannabinoids and its derivatives for chronic pain is increasing. Two most well-known and clinically relevant forms of cannabinoids are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). The main receptor targeted are cannabinoid receptor 1 (CB1) and CB2. Indications for the utilization of THC are multiple sclerosis, cancer-related pain/cancer-related nausea and vomiting (anti-emetic), peripheral neuropathic pain, and HIV-associated weight loss.
- Type
- Chapter
- Information
- Cambridge Handbook of Pain Medicine , pp. 66 - 68Publisher: Cambridge University PressPrint publication year: 2023
References
Kumar, RN, Chambers, WA, Pertwee, RG. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 2001;56(11):1059–1068. https://doi.org/10.1046/J.1365-2044.2001.02269.X.CrossRefGoogle ScholarPubMed
Malfitano, AM, Proto, MC, Bifulco, M. Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr. Dis. Treat. 2008;4(5):847. https://doi.org/10.2147/NDT.S3208.Google ScholarPubMed
EPIDIOLEX® (cannabidiol) | Greenwich Biosciences. 2021. Accessed November 5, 2021. www.greenwichbiosciences.com/epidiolex.Google Scholar
O’Donnell, B, Meissner, H, Gupta, V. Dronabinol. Pharma-Kritik. 2021;24(8):29–31. Accessed November 5, 2021. www.ncbi.nlm.nih.gov/books/NBK557531/.Google Scholar
Ware, MA, Daeninck, P, Maida, V. A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting. Ther. Clin. Risk Manag. 2008;4(1):99. https://doi.org/10.2147/TCRM.S1132.CrossRefGoogle ScholarPubMed
Grotenhermen, F, Müller-Vahl, K. The Therapeutic Potential of Cannabis and Cannabinoids. Deutsches Ärzteblatt International. 2012;109(29–30):495. https://doi.org/10.3238/ARZTEBL.2012.0495.Google ScholarPubMed
Russo, M, Naro, A, Leo, A et al. Evaluating Sativex® in neuropathic pain management: A clinical and neurophysiological assessment in multiple sclerosis. Pain Med. (Malden, Mass). 2016;17(6):1145–1154. https://doi.org/10.1093/PM/PNV080.Google ScholarPubMed
Serpell, MG, Notcutt, W, Collin, C. Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis. J. Neurol. 2013;260(1):285–295. https://doi.org/10.1007/S00415-012-6634-Z.CrossRefGoogle ScholarPubMed
Sheikh, NK, Dua, A. Cannabinoids. Published online July 25, 2021. Accessed November 5, 2021. www.ncbi.nlm.nih.gov/books/NBK556062/.Google Scholar